Welcome to our dedicated page for Ocular Therapeut news (Ticker: OCUL), a resource for investors and traders seeking the latest updates and insights on Ocular Therapeut stock.
Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical innovator developing sustained-release therapies for retinal diseases and ocular conditions. This page serves as the definitive source for company news, providing investors and professionals with timely updates on clinical advancements, regulatory developments, and corporate milestones.
Access press releases, earnings reports, and analysis of key events impacting OCUL's trajectory. Our curated collection includes updates on AXPAXLI™ clinical trials for wet AMD, DEXTENZA® commercial performance, and pipeline progress across glaucoma and diabetic retinopathy therapies. Discover how the company's proprietary hydrogel platform addresses treatment challenges in ophthalmology.
Bookmark this page for streamlined access to OCUL's latest FDA submissions, partnership announcements, and financial disclosures. Stay informed about developments influencing both near-term performance and long-term growth in ocular therapeutics.
Ocular Therapeutix, Inc. (NASDAQ:OCUL) will report its financial results for the first quarter ending March 31, 2023, on May 8, 2023. Following the earnings release, a live conference call is scheduled for 4:30 PM Eastern Time to discuss the results and provide a business update. Ocular Therapeutix specializes in innovative therapies for eye conditions, with its first commercial product, DEXTENZA®, FDA-approved for treating ocular inflammation and associated pain. The company is also advancing several clinical trials, including OTX-TKI for wet AMD, OTX-TIC for glaucoma, and treatments for dry eye disease.
AffaMed Therapeutics announced the approval from China's National Medical Products Administration to start a Phase 3 clinical trial for DEXTENZA, targeting ocular inflammation and pain after ophthalmic surgery. This follows DEXTENZA's recent approval in Macau for treating ocular itching from allergic conjunctivitis. The licensing agreement with Ocular Therapeutix in October 2020 covers development in Greater China, South Korea, and parts of ASEAN. DEXTENZA is noted for its compliance benefits, requiring a single administration for up to 30 days. AffaMed plans to commence this pivotal study shortly, aiming to enhance treatment options in China.
FAQ
What is the current stock price of Ocular Therapeut (OCUL)?
What is the market cap of Ocular Therapeut (OCUL)?
